Media stories about GW Pharmaceuticals PLC- (NASDAQ:GWPH) have been trending somewhat positive this week, Accern Sentiment reports. Accern scores the sentiment of press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. GW Pharmaceuticals PLC- earned a media sentiment score of 0.22 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 46.5410567412963 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the news stories that may have effected Accern Sentiment’s rankings:
- A Marijuana Market Most Investors Aren't Thinking About (finance.yahoo.com)
- GW Pharmaceuticals PLC- (GWPH) Receives Average Recommendation of “Hold” from Brokerages (americanbankingnews.com)
- GW Pharmaceuticals PLC- (GWPH) Stock Rating Lowered by Zacks Investment Research (americanbankingnews.com)
- GW Pharmaceuticals PLC- (GWPH) Short Interest Update (americanbankingnews.com)
GWPH has been the subject of a number of recent analyst reports. Bank of America decreased their price target on GW Pharmaceuticals PLC- from $160.00 to $158.00 and set a “buy” rating for the company in a report on Tuesday, November 14th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $208.00 price target on shares of GW Pharmaceuticals PLC- in a report on Monday, November 20th. Goldman Sachs Group raised GW Pharmaceuticals PLC- from a “neutral” rating to a “buy” rating and set a $174.00 price target for the company in a report on Thursday, December 14th. BidaskClub raised GW Pharmaceuticals PLC- from a “hold” rating to a “buy” rating in a report on Friday, December 22nd. Finally, Zacks Investment Research downgraded GW Pharmaceuticals PLC- from a “hold” rating to a “sell” rating in a report on Tuesday, December 26th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $146.38.
GW Pharmaceuticals PLC- (NASDAQ:GWPH) last posted its earnings results on Monday, February 5th. The biopharmaceutical company reported ($2.43) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($2.03) by ($0.40). GW Pharmaceuticals PLC- had a negative net margin of 1,357.98% and a negative return on equity of 46.94%. The firm had revenue of $7.73 million during the quarter, compared to analysts’ expectations of $2.18 million. analysts anticipate that GW Pharmaceuticals PLC- will post -9.18 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This report was originally posted by Community Financial News and is owned by of Community Financial News. If you are viewing this report on another publication, it was illegally copied and republished in violation of U.S. and international trademark and copyright laws. The original version of this report can be accessed at https://www.com-unik.info/2018/02/19/gw-pharmaceuticals-plc-gwph-given-daily-coverage-optimism-rating-of-0-22.html.
About GW Pharmaceuticals PLC-
GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).
Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.